Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

Trial Description

Summary

RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Calcitriol may help temozolomide kill more tumor cells by making them more sensitive to the drug. Calcitriol may also stop the growth of melanoma by blocking blood flow to the tumor.

PURPOSE: This phase I/II trial is studying the best dose of calcitriol, the side effects of calcitriol when given together with temozolomide, and to see how well they work in treating patients with metastatic stage IV melanoma.

Further Study Information

* Phase I: Patients receive oral calcitriol on days 1 and 15 and oral temozolomide on days 2-8 and 16-22. Treatment repeats every 28 days for 2 courses in the absence of unacceptable toxicity. Responding patients continue therapy for up to 6 courses in the absence of unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of calcitriol until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose limiting toxicity.

• Phase II: Patients receive temozolomide and calcitriol at the MTD as in phase I.

After completion of study treatment, patients are followed every 3 months.

Eligibility Criteria

Inclusion Criteria:

• Histologically confirmed malignant melanoma

• Any primary tumor site

• Stage IV disease

• CNS metastases allowed

• Measurable disease, defined as at least 1 lesion that can be accurately measured in at least 1 dimension as ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan

• Must have had at least 1 prior systemic therapy

• Negative pregnancy test

• Fertile patients must use effective contraception

• Patients with no prior systemic therapy are eligible provided they are not candidates for high-dose interleukin-2

• Recovered from all toxic effects of prior therapy

• More than 4 weeks since prior and no concurrent radiotherapy, chemotherapy, or immunotherapy

• More than 4 weeks since prior and no concurrent radiotherapy, chemotherapy, or immunotherapy

• Fertile patients must use effective contraception

Exclusion Criteria:

• Life expectancy less than 4 months

• known HIV positivity

• evidence of active infection requiring antibiotic therapy

• other malignancy within the past 5 years except surgically resected basal cell or squamous cell skin cancer

• significant medical disease which, in the opinion of the investigator, may interfere with study completion

• pregnant or nursing

• Negative pregnancy test

• prior temozolomide or dacarbazine

• investigational agent within 4 weeks prior to study entry

• concurrent magnesium-containing antacids, digitalis, bile-resin binding drugs, or calcium supplements

Trial Contact Information

Trial Lead Organizations/Sponsors

Robert H. Lurie Comprehensive Cancer Center at Northwestern University

Timothy M. Kuzel

Study Chair

U.S.A.
Illinois
	Chicago
	Robert H. Lurie Comprehensive Cancer Center at Northwestern University
		Clinical Trials Office - Robert H. Lurie Comprehensive Cancer	Ph: 312-695-1301
			Email: cancer@northwestern.edu

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00301067
Information obtained from ClinicalTrials.gov on December 14, 2011

Back to Top